With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
Zynerba Pharmaceuticals
At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to...
| EPIC: | ZYNE |
| Market: | NASDAQ:ZYNE |
| 52-week High/Low: | $16.46 / $2.82 |
| Sector: | Pharma & Biotech |
| Market Cap: | $279.67 m |
| Website: | zynerba.com |
col 3
col 4
col 5
col 6
Big Picture – A Deep Dive Examination of Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Snapshot
Videos
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with...
Partners:
